Regulatory Information

Advancing Women's Health with Transparency and Accountability

At GyneConcepts, innovation is only meaningful when it is supported by quality, responsibility, and trust.

As developers of the Privacy Pap Smear (PPS), we are committed to maintaining high standards throughout the design, development, and evaluation of our technology. Our focus is not only on creating innovative solutions for women's healthcare, but also on ensuring that those solutions are developed with regulatory compliance, product quality, and patient safety in mind.

Our Commitment

to Quality

The Privacy Pap Smear was developed to address one of the most significant challenges in women's healthcare: How do we help more women participate in routine cervical cancer screening?

From concept to development, every aspect of the PPS has been designed with a commitment to:

Our mission is to make cervical health screening more accessible, convenient, affordable, and psychologically comfortable for women worldwide while maintaining the standards expected of medical technologies.

Designed for Cervical Cell Collection

The Privacy Pap Smear is the world's first patented cervical cell collection device designed for self-administration.

Unlike many self-sampling approaches that collect vaginal cells primarily for HPV testing, the PPS

was specifically designed to collect cervical cells can be tested for but not limited to the following:

This design supports GyneConcepts' mission of expanding access to meaningful cervical health screening while prioritizing convenience and privacy.

CE Registration and European Compliance

This registration reflects compliance with applicable European device registration requirements and demonstrates GyneConcepts' commitment to quality and regulatory oversight.

Intellectual Property Protection

Innovation requires protection.

The Privacy Pap Smear is supported by a growing intellectual property portfolio that protects the unique technology behind the device and supports future expansion into global markets.

U.S. Patent No. 8,460,209 B2

Issued: June 11, 2013

U.S. Patent No. 8,672,861 B2

Issued: March 18, 2014

These patents provide protection for key design and functionality elements of the Privacy Pap Smear.

Regulatory & Development Timeline

Clinical Evaluation and Ongoing Research

Research remains an important part of the GyneConcepts mission. The Privacy Pap Smear continues to be evaluated through ongoing clinical research and development initiatives designed to further assess performance, usability, and patient experience.

Current Clinical Trial Activity

GyneConcepts is actively conducting clinical trial activities in the Atlanta, Georgia area. Clinical research plays an important role in validating innovative healthcare technologies and supporting future advancements in women's health.

Global Vision, Responsible Development

GyneConcepts believes healthcare innovation must be supported by responsible development practices and regulatory accountability.

As we continue advancing the Privacy Pap Smear, we remain committed to:

These principles guide every stage of our development process.

Peace of Mind for All Women

Everything we do is guided by a commitment to improving women's health through innovation, transparency, and responsible product development. By combining research, regulatory diligence, and a patient-first philosophy, GyneConcepts continues to work toward a future where cervical health screening is more accessible, more convenient, and more empowering for women everywhere.